NZ607595A - A process for concentration of a polypeptide - Google Patents

A process for concentration of a polypeptide

Info

Publication number
NZ607595A
NZ607595A NZ607595A NZ60759507A NZ607595A NZ 607595 A NZ607595 A NZ 607595A NZ 607595 A NZ607595 A NZ 607595A NZ 60759507 A NZ60759507 A NZ 60759507A NZ 607595 A NZ607595 A NZ 607595A
Authority
NZ
New Zealand
Prior art keywords
functionally equivalent
equivalent parts
porphobilinogen deaminase
polypeptide
analogues hereof
Prior art date
Application number
NZ607595A
Other languages
English (en)
Inventor
Stefan Nilsson
Original Assignee
Zymenex As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymenex As filed Critical Zymenex As
Priority to NZ62312307A priority Critical patent/NZ623123A/en
Publication of NZ607595A publication Critical patent/NZ607595A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
    • C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
    • C12Y205/01061—Hydroxymethylbilane synthase (2.5.1.61)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06001—Arylsulfatase (3.1.6.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01024—Alpha-mannosidase (3.2.1.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01046—Galactosylceramidase (3.2.1.46)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06008—Cerebroside-sulfatase (3.1.6.8)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Water Supply & Treatment (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NZ607595A 2006-04-04 2007-04-04 A process for concentration of a polypeptide NZ607595A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ62312307A NZ623123A (en) 2006-04-04 2007-04-04 A process for concentration of a polypeptide

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200600488 2006-04-04
DKPA200600922 2006-07-05
NZ597548A NZ597548A (en) 2006-04-04 2007-04-04 A process for concentration of a polypeptide

Publications (1)

Publication Number Publication Date
NZ607595A true NZ607595A (en) 2014-10-31

Family

ID=38472949

Family Applications (7)

Application Number Title Priority Date Filing Date
NZ607595A NZ607595A (en) 2006-04-04 2007-04-04 A process for concentration of a polypeptide
NZ588903A NZ588903A (en) 2006-04-04 2007-04-04 A process for concentration of galactosycerebrosidase or porphobuilinogen deaminase
NZ597548A NZ597548A (en) 2006-04-04 2007-04-04 A process for concentration of a polypeptide
NZ582045A NZ582045A (en) 2006-04-04 2007-04-04 A pharmaceutical composition comprising at least 10mg/mL of alfa mannosidase and less that 5% total protein aggregates
NZ568728A NZ568728A (en) 2006-04-04 2007-04-04 A process for concentration of a aryl sulfatase A
NZ571610A NZ571610A (en) 2006-04-04 2007-04-04 A process for concentration of alpha mannosidase
NZ62312307A NZ623123A (en) 2006-04-04 2007-04-04 A process for concentration of a polypeptide

Family Applications After (6)

Application Number Title Priority Date Filing Date
NZ588903A NZ588903A (en) 2006-04-04 2007-04-04 A process for concentration of galactosycerebrosidase or porphobuilinogen deaminase
NZ597548A NZ597548A (en) 2006-04-04 2007-04-04 A process for concentration of a polypeptide
NZ582045A NZ582045A (en) 2006-04-04 2007-04-04 A pharmaceutical composition comprising at least 10mg/mL of alfa mannosidase and less that 5% total protein aggregates
NZ568728A NZ568728A (en) 2006-04-04 2007-04-04 A process for concentration of a aryl sulfatase A
NZ571610A NZ571610A (en) 2006-04-04 2007-04-04 A process for concentration of alpha mannosidase
NZ62312307A NZ623123A (en) 2006-04-04 2007-04-04 A process for concentration of a polypeptide

Country Status (20)

Country Link
US (6) US20090246187A1 (enExample)
EP (4) EP2004672B1 (enExample)
JP (6) JP2009532394A (enExample)
KR (3) KR101504969B1 (enExample)
CN (1) CN105233276A (enExample)
AU (2) AU2007234195B2 (enExample)
BR (1) BRPI0709737A2 (enExample)
CA (3) CA2882501C (enExample)
DK (1) DK2628746T3 (enExample)
ES (3) ES2744499T3 (enExample)
HU (1) HUE042402T2 (enExample)
IL (4) IL194267A (enExample)
MX (1) MX2008012748A (enExample)
NO (3) NO347673B1 (enExample)
NZ (7) NZ607595A (enExample)
PL (3) PL2628746T3 (enExample)
PT (1) PT2628746T (enExample)
SI (1) SI2628746T1 (enExample)
WO (1) WO2007112757A2 (enExample)
ZA (2) ZA200805346B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2532742B1 (en) 2004-01-30 2018-08-08 Shire Pharmaceuticals Ireland Limited Recombinant arylsulfatase A for reducing galatosyl sulphatide levels in a subject
ES2744499T3 (es) * 2006-04-04 2020-02-25 Chiesi Farm Spa Un proceso para la concentración de un polipéptido
NZ601790A (en) * 2010-02-24 2014-03-28 Zymenex As Process for production and purification of recombinant lysosomal alpha-mannosidase
BR112012033197A2 (pt) 2010-06-25 2017-06-06 Shire Human Genetic Therapies métodos e composições para liberação de cns de n-sulfatase de heparano.
KR102720061B1 (ko) * 2010-06-25 2024-10-22 다케다 파머수티컬 컴패니 리미티드 아릴설파타제 a의 cns 전달을 위한 방법들 및 조성물들
PT2588130T (pt) 2010-06-25 2016-11-25 Shire Human Genetic Therapies Entrega de agentes terapêuticos no cns
SMT201600385T1 (it) * 2010-06-25 2017-03-08 Shire Human Genetic Therapies Trasporto di agenti terapeutici all’snc
EP2729566B1 (en) 2011-07-08 2017-03-15 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase a
EP2793922B1 (en) 2011-12-23 2019-10-30 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
NZ707753A (en) * 2012-11-13 2019-07-26 Chiesi Farm Spa Purification of recombinant human galactocerebroside β-galactosidase (rhgalc)
BR112015013498A2 (pt) * 2012-12-11 2017-07-11 Centogene Ag método para o diagnóstico de leucodistrofia metacromática
EP2943568B1 (en) 2013-01-09 2019-11-20 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase a
UY35463A (es) 2013-03-15 2014-10-31 Biogen Idec Inc Formulaciones de polipéptido fc-factor ix.
SG10201913735SA (en) 2014-03-24 2020-03-30 Bioverativ Therapeutics Inc Lyophilized factor ix formulations
US11584777B2 (en) 2017-08-31 2023-02-21 Green Cross Corporation Method for purifying a sulfatase protein
KR102290596B1 (ko) * 2020-09-10 2021-08-19 주식회사 파이안바이오테크놀로지 분리된 미토콘드리아를 포함하는 주사용 조성물 및 이의 용도

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2041280A1 (en) 1990-05-10 1991-11-11 Yosuke Sawada Arylsulfatase
NO960163D0 (no) * 1996-01-15 1996-01-15 Thomas Berg Mutasjonsdeteksjon av bovin
ES2177240T3 (es) 1998-01-27 2002-12-01 Hemebiotech As Tratamiento para la porfiria aguda intermitente (pai) y otras enfermedades porfiricas.
DK1084147T3 (da) * 1998-06-09 2004-10-25 Statens Seruminstitut Fremgangsmåde til fremstilling af immunglobuliner til administration og andre immunglobulinprodukter
DK2270044T3 (en) * 1998-06-09 2015-01-26 Csl Behring Ag Liquid immunoglobulin G (IgG) product
US6537777B1 (en) 1998-07-27 2003-03-25 Hemebiotech A/S Human porphobilinogen deaminase sequences
AUPQ026799A0 (en) * 1999-05-10 1999-06-03 Csl Limited Method of increasing protein stability by removing immunoglobulin aggregates
CA2378373C (en) 1999-07-27 2011-12-13 Hemebiotech A/S Production of rhpbgd and new therapeutic methods for treating patients with acute intermittent porphyria (aip) and other porphyric diseases
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
CA2429210A1 (en) 2000-11-15 2002-05-23 Jason C. Goodrick Expression system for recombinant proteins
AU2002317701A1 (en) * 2001-06-07 2002-12-16 Hemebiotech A/S Production of recombinant human lysosomal alpha-mannosidase
WO2002098455A2 (en) * 2001-06-07 2002-12-12 Hemebiotech A/S Production of recombinant human arylsulfatase a
EP1402014A1 (en) * 2001-06-29 2004-03-31 Hemebiotech A/S A process for purification of recombinant porphobilinogen deaminase
US7232670B2 (en) * 2001-09-28 2007-06-19 St. Jude Children's Research Hospital Targeting proteins to cells expressing mannose receptors via expression in insect cells
ES2496493T3 (es) 2002-01-11 2014-09-19 Bioasis Technologies Inc. Uso de p97 como sistema de administración de enzimas para la administración de enzimas lisosómicas terapéuticas
WO2003066669A2 (en) * 2002-02-04 2003-08-14 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
CH694697A5 (de) 2004-01-29 2005-06-15 Koelbl Engineering Und Consult Gummimehl-enthaltende Elastomerlegierungen.
EP2532742B1 (en) * 2004-01-30 2018-08-08 Shire Pharmaceuticals Ireland Limited Recombinant arylsulfatase A for reducing galatosyl sulphatide levels in a subject
SI1740204T1 (en) 2004-04-01 2018-07-31 Chiesi Farmaceutici S.P.A. MEDICAL APPLICATION OF ALFA-MANOSIDES
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
ES2744499T3 (es) * 2006-04-04 2020-02-25 Chiesi Farm Spa Un proceso para la concentración de un polipéptido

Also Published As

Publication number Publication date
ES2928096T3 (es) 2022-11-15
US20140314735A1 (en) 2014-10-23
US20170202927A1 (en) 2017-07-20
JP2014051503A (ja) 2014-03-20
NZ582045A (en) 2011-07-29
IL194267A0 (en) 2011-08-01
AU2007234195B2 (en) 2013-02-07
JP5878152B2 (ja) 2016-03-08
EP2628746A3 (en) 2014-03-19
ZA200809540B (en) 2019-09-25
ES2713488T3 (es) 2019-05-22
US9713634B2 (en) 2017-07-25
KR20140057678A (ko) 2014-05-13
US20120076767A1 (en) 2012-03-29
AU2008229659A1 (en) 2008-10-23
IL194267A (en) 2015-10-29
PL2628746T3 (pl) 2019-07-31
US20090246187A1 (en) 2009-10-01
SI2628746T1 (sl) 2019-04-30
AU2008229659B2 (en) 2013-01-31
ES2744499T3 (es) 2020-02-25
DK2628746T3 (en) 2019-04-01
EP2628746A2 (en) 2013-08-21
EP2628746B1 (en) 2019-01-09
HUE042402T2 (hu) 2019-06-28
JP2016104000A (ja) 2016-06-09
JP2013236633A (ja) 2013-11-28
NZ623123A (en) 2015-04-24
NO20211305A1 (no) 2008-10-31
AU2007234195A1 (en) 2007-10-11
EP2631242B1 (en) 2022-08-03
CA2644642A1 (en) 2007-10-11
NZ588903A (en) 2012-08-31
EP2004672B1 (en) 2015-08-19
KR101504969B1 (ko) 2015-03-24
US20180289777A1 (en) 2018-10-11
EP2631242A2 (en) 2013-08-28
KR20150103339A (ko) 2015-09-09
PT2628746T (pt) 2019-04-23
CA2882501A1 (en) 2007-10-11
IL235982A0 (en) 2015-01-29
ZA200805346B (en) 2018-11-28
CA2644642C (en) 2016-01-26
CA2882501C (en) 2021-09-07
KR20090018894A (ko) 2009-02-24
EP2100898B1 (en) 2019-06-19
CN105233276A (zh) 2016-01-13
CA2632528C (en) 2022-07-12
JP2009273469A (ja) 2009-11-26
IL211905A0 (en) 2011-05-31
IL241654B (en) 2019-02-28
NO20082510L (no) 2008-10-31
JP5384232B2 (ja) 2014-01-08
BRPI0709737A2 (pt) 2011-07-26
JP2014058521A (ja) 2014-04-03
NO20084776L (no) 2008-10-31
EP2631242A3 (en) 2013-10-02
NZ597548A (en) 2013-08-30
NO346368B1 (no) 2022-06-27
EP2004672A2 (en) 2008-12-24
EP2100898A1 (en) 2009-09-16
CA2632528A1 (en) 2007-10-11
US20160193304A1 (en) 2016-07-07
NO347673B1 (no) 2024-02-19
PL2631242T3 (pl) 2023-03-20
MX2008012748A (es) 2009-01-07
US8809055B2 (en) 2014-08-19
NZ568728A (en) 2011-09-30
IL241654A0 (en) 2015-11-30
NZ571610A (en) 2011-07-29
WO2007112757A3 (en) 2008-02-28
PL2100898T3 (pl) 2019-11-29
WO2007112757A2 (en) 2007-10-11
JP2009532394A (ja) 2009-09-10

Similar Documents

Publication Publication Date Title
NZ607595A (en) A process for concentration of a polypeptide
NZ605865A (en) Cns delivery of therapeutic agents
MX2009002314A (es) Composiciones farmaceuticas que comprenden hgh para suministro oral.
EP2175834B8 (en) Glp-1-fc fusion protein formulation
JO3598B1 (ar) الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
PH12014500922A1 (en) Insulinotropic peptide derivative wherein its n-terminal amino acid is modified
NZ597830A (en) Methods and compositions for treating cancer comprising abiraterone acetate and prednisone
TW200609227A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
MX2010013766A (es) Rasagilina para modificacion de enfermedad de parkinson.
NZ702800A (en) Methods and compositions for cns delivery of heparan n-sulfatase
WO2007122580A3 (en) Compositions of phenylephrine useful for treatment of respiratory illness
EP4483952A3 (en) Compositions suitable for treating collagen-mediated diseases
NZ608502A (en) Polypeptides that bind to human complement component c5
TW200806299A (en) Treatment of pain
IL192181A0 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
WO2007138466A3 (en) Pharmaceutical compositions comprising meloxicam and tramadol combination
NZ612063A (en) Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration
MXPA05000765A (es) Compuestos de 5-ariltetrazola, composiciones de los mismos y usos para los mismos.
TNSN08506A1 (en) Substituted carboxamides
EA200600626A1 (ru) Композиция и лекарственная форма продолжительного выделения леводопы
SG141358A1 (en) Treatment of psychiatric patients with reduced heptaic function with paliperidone
MX2008001520A (es) Composiciones de tizanidina y metodos de tratamiento usando las composiciones.
MX366496B (es) Metodos para preparar composiciones farmaceuticas que comprenden acetato de eslicarbazepina y metodos de uso.
WO2007056263A3 (en) Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
DE502006008291D1 (de) Proteinzusammensetzung zur behandlung eines physiologisch bedingten, klinisch unauffälligen proteinmehrbedarfs

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 6 YEARS UNTIL 04 APR 2017 BY BALDWINS INTELLECTUAL PROPERTY

Effective date: 20150530

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 APR 2018 BY DENNEMEYER + CO.

Effective date: 20170331

ASS Change of ownership

Owner name: CHIESI FARMACEUTICI S.P.A., IT

Effective date: 20170608

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 APR 2019 BY COMPUTER PACKAGES INC

Effective date: 20180331

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 APR 2020 BY COMPUTER PACKAGES INC

Effective date: 20190319

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 APR 2021 BY COMPUTER PACKAGES INC

Effective date: 20200318

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 APR 2022 BY COMPUTER PACKAGES INC

Effective date: 20210330

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 APR 2023 BY COMPUTER PACKAGES INC

Effective date: 20220317

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 APR 2024 BY COMPUTER PACKAGES INC

Effective date: 20230317

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 APR 2025 BY COMPUTER PACKAGES INC

Effective date: 20240330

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 APR 2026 BY COMPUTER PACKAGES INC

Effective date: 20250317